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ABSTRACT 
 
 
 
Syster-Clevenger, Elizabeth A. M.S., Purdue University, August 2014.  Characterization 
of Protein-Protein Interactions Mediated by the Second Exon of the Varicella-zoster 
Virus ORF45/42 Terminase Subunit.  Major Professor: Robert J. Visalli. 
 
 
 
Varicella-zoster virus (VZV), a member of the Herpesviridae, is ubiquitous 
human pathogen with significant morbidity and mortality in healthy and 
immunocompromised individuals.  Primary infection causes a systemic viremia and skin 
rash known as varicella, and more commonly referred to as chickenpox.  Latency is 
established in the nervous system during primary infection and can reactivate to cause 
zoster, more commonly known as shingles. Current treatments for VZV infection target 
viral DNA replication, primarily the DNA polymerase.  However, novel small molecule 
inhibitors that target other viral replication processes, for example viral DNA 
encapsidation, offer additional therapeutic options.  Seven conserved open reading frames 
(ORFs) encode proteins that were shown to be essential for herpesviral DNA 
encapsidation.  This thesis explores the protein-protein interaction of one of the VZV 
encapsidation proteins, the small terminase protein, pORF45/42.  Previous studies have 
explored interaction among the VZV terminase subunits, particularly exon II of 
pORF45/42.  New studies were designed to identify potential small terminase protein 
self-interactions sites encoded by exon II.  Full length pORF42 and four truncated 
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ORF42Δ constructs were constructed based upon a proposed self-interaction site in the 
Human cytomegaloviurs (HCMV) homologue, pUL89.  pORF42 constructs were 
expressed in E. coli, purified and then tested in GST pull down assays using a GST-
pORF42 fusion protein (GST-ORF42-C269).  GST pull-down assays demonstrated that 
pORF42, pORF42Δ1, and pORF42Δ2 interacted with immobilized GST-pORF42 fusion 
protein.  Interestingly, pORF42Δ1 and pORF42Δ2 were developed with N-terminal 
deletions that removed the proposed interaction site of HCMV pUL89 yet both interacted 
with GST-ORF42-C269.  pORF42Δ3 and pORF42Δ4 did not show any interaction with 
GST-ORF42-C269, suggesting that the self-interaction site was located within the C-
terminus of pORF42.  This unique VZV pORF45/42 self-interaction site may play a role 
in the formation of multimeric small terminase complexes and these may be required for 
proper terminase function.  Assays targeting the VZV interaction site may reveal novel 
antivirals that target the VZV pORF45/42 terminase and the DNA encapsidation process. 
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INTRODUCTION 
 
 
 
The family Herpesviridae, contains three subfamilies, alpha, beta, and gamma.  
Varicella-zoster virus (VZV), herpes simplex virus type 1 (HSV-1) and herpes simplex 
virus type 2 (HSV-2) belong to the human alpha herpesvirus subfamily. The beta 
subfamily consists of human cytomegalovirus (HCMV) and human herpesviruses type 6 
(HHV-6) and 7 (HHV-7).  The gamma subfamily includes Epstein-Barr virus (EBV) and 
Kaposi’s sarcoma-associated herpesvirus (KSHV).  Each of these viruses is associated 
with significant diseases that plague the worlds’ population.  Immunocompromised 
individuals, such as those with HIV or undergoing organ transplantation are at particular 
risk.  Continued research toward the discovery of novel antiviral targets and new antiviral 
drug therapies is important to reduce the morbidity and mortality caused by the eight 
human herpesviruses (Arvin, 1996; Visalli, 2003). 
 
Alphaherpesvirus Biology 
Our model organism, VZV, causes varicella (chicken pox) as well as herpes 
zoster (shingles) and characteristic alpha herpesviruses, establishes latency in cells of the 
dorsal root ganglia after primary infection.  Primary infection, most often a childhood 
illness, is associated with a rash affecting the trunk, face, and scalp.  Reactivation of 
latent virus typically occurs in elderly or immunosuppressed individuals and causes a 
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localized and painful rash.  VZV spreads through the respiratory route via infectious 
droplets or aerosol from infected individuals.  The virus initiates infection in the lungs, 
travels to regional lymph nodes and spreads to the liver during a 14 day incubation 
period.  Replication in the liver leads to viremia and the virus seeds epidermal cells of the 
skin resulting in a visible rash (Arvin, 1996; Grove et al, 2000).  Virus in the skin will 
invade the nervous system and establish latency via movement up the nerve axon.  
 
Herpesviral DNA Encapsidation 
Although the herpesviruses have been classified into different subfamilies, their 
gene products share significant functional homology that is likely a result of evolution 
from a common ancestor (Davison, 2000).  All 8 of the human herpesviruses have been 
fully sequenced and share approximately 40 core open reading frames (ORFs) that 
control processes from DNA replication through maturation and egress.  These conserved 
gene products are essential for viral replication and virus structure, and are therefore 
considered potential antiviral targets for one or more of the Herpesviridae. (Arvin, 2007). 
Viruses in the subfamily Alphaherpesvirinae share many features due to a 
common ancestral lineage (Davison, 2007, pg 10-26).    The VZV genome contains open 
reading frames that are most closely related to genes in the HSV UL genomic region.  
Hence, studies on HSV UL genes and gene products can often be useful when studying 
VZV (Baines, 2007, 61). This is particularly true for genes involved in DNA 
encapsidation.   
The process of DNA encapsidation, i.e. the insertion of one unit length of 
genomic DNA into a preformed capsid, is the major focus of the Visalli laboratory.  The 
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process of encapsidation occurs through the interaction of a complex of proteins that 
form a terminase.  This terminase powers the packaging of the DNA genome into the 
procapsid through a portal protein encoded by UL6 in HSV-1 and ORF54 in VZV.  The 
portal is located at a single vertex of the icosahedral capsid and is thought to be a multi-
meric complex that dynamically pulls the DNA into the capsid.  A protein representing a 
“plug” is used to seal the DNA within the capsid.   
There are at least seven genes found to be essential for viral DNA cleavage and 
packaging into capsids.  The encapsidation genes (Table 1) have been extensively studied 
in HSV and to a lesser extent in HCMV and VZV.  In HSV-1, the gene products encoded 
by UL6, UL17, UL32, UL15, UL25, UL28, and UL33 act collectively to mediate cleavage 
and packaging of viral DNA into the capsid.  If any one of these genes / proteins is 
absent, the capsids will appear normal in electron microscopy, but viral DNA will not be 
cleaved or packaged into the capsid (Beard, 2002; Higgs et al.,2008; Koslowski, 1999; 
Salmon and Baines, 1998; Sheaffer, 2001; Yu and Weller, 1998b).  
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Table 1.  Herpesvirus common encapsidation gene products (Arvin, 2007). 
Common Name HSV VZV (ORF) HCMV Key Function 
Portal Protein UL6 ORF54 UL104 Oligomeric 
channel for 
DNA 
insertion; 
located at 5 
fold capsid 
vertex 
Portal Capping 
Protein 
UL25 ORF34 UL77 Covers the 
portal in 
mature virions 
Capsid Translocation  
Protein 
UL17 ORF43 UL93 Capsid 
transport to 
the nucleus 
Capsid Translocation 
Protein 
UL32 ORF26 UL52 Capsid 
transport to 
nucleus 
Terminase ATPase  
Subunit 1 
UL15 ORF45/42 UL89 DNA 
processing 
and packaging 
machinery 
Terminase DNA 
Binding Subunit 2 
UL28 ORF30 UL56 DNA 
processing 
and packaging 
machinery 
Terminase Binding 
Protein 
UL33 ORF25 UL51 Part of the 
trimeric 
terminase 
complex 
 
 
 
DNA-packaging proteins collectively referred to as the terminase complex (i.e. 
UL15, UL28, and UL33 for HSV) are key players in the encapsidation process. The 
terminase subunits, essential for the process of encapsidation, are also potential antiviral 
targets.  For HSV-1, studies have shown that the terminase is a hetero-trimeric complex 
formed by the two terminase subunits, pUL15 and pUL28, and a stabilizing protein, UL33.  
pUL15 and pUL28 act as a molecular motor and interacts with the portal protein (pUL6) at 
the capsid vertex.  This complex is stabilized by pUL33, which can interact with the 
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pUL15/ pUL28 complex or independently with either pUL15 or pUL28; furthermore, if 
pUL33 is absent, the genome with be neither cleaved nor packaged (Arvin, 2007; Bogner, 
2002; Beard, 2002; Higgs, 2008; Hwang and Bogner,2002; Scheffczik et al., 2002; 
Scholz et al., 2003; White et al., 2003).  This heterotrimeric complex binds to 
concatemeric viral DNA, cleaving the DNA at precise sites, and furthering the 
encapsidation process by hydrolyzing ATP and driving DNA packaging (Beard, 2002).  
Studies with HSV-1 and HCMV have revealed numerous protein-protein interactions that 
take place between the terminase subunits. Each of these interactions is a potential 
antiviral target.  
Initial experiments were conducted to determine both the functional and physical 
interactions between pUL28 and pUL15.It was shown that pUL28 could not enter the 
nuclei of infected cells in the absence of otherHSV-1 proteins.  In cells co-transfected 
with vectors individually expressingUL28 or UL15, pUL28 was translocated to the in the 
presence of pUL15 (Koslowski et al.,1997,1999).  Furthermore, a series of HSV-1 UL28 
mutants were employed in co-immunoprecipitation assays with the UL15 gene product.  
These studies revealed at least two separate regions of UL28 that contributed to binding 
UL15.  Additionally, cells were infected both individually, and together with recombinant 
baculocvirus containing only a tagged exon II of UL15 or full length UL15.  The cell 
extracts were immunoprecipitated with an antibody recognizing the tagged exon II of 
pUL15, and it was shown that both exon II and the full length pUL15 were present, 
indicating that the UL15 proteins have the ability to not only interact with UL28, but also 
with each other.  (Abbotts et al., 2000).  The findings from these experiments indicate 
that multiple interactions occur between the large and small terminase subunits.    
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VZV has not been as extensively studied as some of the other human 
herpesviruses.  Fortunately, the interactions previously described for HSV-1 have 
provided a template for studies to define interactions in the VZV DNA encapsidation 
process.  Based on sequence homology, the VZV terminase is likely encoded by the  
homologues of HSV-1 UL15, UL28, and UL33, i.e. ORF45/42, ORF30, and ORF25, 
respectively.  ORF45/42 is a spliced gene containing two coding exons separated by a 
single intron (Visalli, 2007).   
Recently studies suggest that the VZV terminase is a hetero-trimeric complex 
consisting of ORF25, ORF30, and ORF45/42.  In vitro studies have shown interaction of 
the C-terminal portion of pORF42 with pORF30 andpORF45/42.  pORF25 was shown to 
interact with not only itself, but also with pORF30 and pORF42.  These results suggest 
that exon II of ORF45/42 is responsible for several interactions with other terminase 
proteins and likely form multimeric complexes (Visalli, 2007, 2009).    
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Fig. 1.  GST pull down assay to detect protein-protein interactions. [1] pORF25 found to 
interact with itself, pORF30, and pORF42 (Visalli, 2009; http://www.ncbi.nlm.nih.gov 
/pmc/articles/PMC2736913/Fig./F3/).  [2] C-terminal pORF42 (C269) interacted with 
pORF45/42 and pORF30, detected on immunoblot (Visalli, 2007; 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669082/Fig./F7/). 
 
 
 
Similar results were also reported for HCMV, where the C-terminus of UL89 (the 
homolog of ORF45/42) was shown to interact with pUL56 (the homolog of ORF30) in 
vitro.  Sequence alignment was performed to analyze potential conserved sites 
responsible for terminase subunit interaction (Fig. 2).  These studies suggest that the C-
terminus of pORF45/42 and the other herpesvirus homologs contains a region important 
for interaction with itself and the pORF30 terminase subunit. In support of this 
conclusion, purified HCMV UL89 formed a visible multimeric structure under electron 
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microscopy (Nadal et al., 2010).  Defining interactions between the terminase subunits is 
important since interference with such interactions may disrupt the viral encapsidation 
process and inhibit viral replication (Visalli, 2007). 
 
Fig. 2.  Sequence homology for UL89 among Herpesvirus families.  Blue Triangles 
represent the proposed residues responsible for dimerization, and the Cyan Triangles are 
the proposed residues responsible for interaction with pUL56 Orange Residues have more 
than 80% similarity and green is full conservation (Nadal et al., 2010; 
http://www.pnas.org/content/suppl/2010/08/24/1007144107.DCSupplemental/pnas.10071
44107_SI.pdf). 
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The results of Nadal et al. provided a starting point to identify specific pORF42 
residues involved in pORF45/42 – pORF45/42 interaction (2010).  I hypothesize that the 
dimerization site of HCMV pUL89 described by Nadal et al. is homologous to VZV 
pORF45/42.  Studies were designed to determine if this region acts independently, or if 
other sites in exon II are required for dimerization.  Several approaches will be used to 
generate pORF42 recombinant proteins for protein-protein interaction studies. 
10 
 
MATERIALS AND METHODS 
 
 
 
Protein Synthesis via the EasyXpress System 
pcDNA3.1D/V5-ORF45/42, IPFW68, (Visalli, 2007, Fig. 3) was used for 
generation of full length ORF45/42 with either N or C-terminal hexahistidine (6xHis) 
tags or N or C-terminal Strep tags.  A two-step PCR (Qiagen EasyXpress) was performed 
using the appropriate oligonucleotide primers (IDT, Inc) listed in Table 2.  
 
 
Fig. 3.  pcDNA3.1/V5-His-TOPO vector (Invitrogen).  The vector contained the 
ORF45/42 insert used for PCR (http://tools.lifetechnologies.com/content/ 
sfs/vectors/pcdna3.1v5histopo_map.pdf). 
11 
 
Table 2.  Oligonucleotide primers developed for tagged ORF45/42 for the two-
step PCR. 
 
N-terminal 
no tag 
5’-AGAAGGAGATAAACAATGTCATTGATAATGTTTGG-3’ 
C-terminal 
no tag 
5’-CTTGGTTAGTTAGTTATTATTTAATAGGCATAAACACGG -
3’ 
N-terminal 
6xHistidine 
5’-
ACCCACGCGCATGTCGTAAAAAGCACCCAATCATTGATAAT
GTTTGG-3’ 
C-terminal 
6xHistidine 
5’-
TGGTGATGGTGGTGACCCCATTTAATAGGCATAAACACGG-
3’ 
N-terminal 
Strep 
5’-
AAAAGCGCTGAAAACCTGATCGAAGGCCGTCATTGATAATG
TTTGG-3’ 
C-terminal 
Strep 
5’-GGATGAGACCAGGCAGATTAATAGGCATAAACACGG-3’ 
 
 
 
Primary amplification reactions included 25 µl volume mix of 1x HotStar 
HiFidelity PCR Buffer, 1 µM sense and antisense primers, 0.75 units HotStar HiFidelity 
DNA Polymerase, and 100 ng/µl of the ORF45/42 plasmid DNA.  Reaction conditions 
were five minutes at 95°C, denaturation for 15 seconds at 94°C, annealing for one minute 
at 45°C, and extension for one minute at 72°C for 40 cycles, with an extension for 10 
minutes at 72°C.  PCR products confirmed on 0.8% agarose gels containing ethidium 
bromide (EtBr) and DNA concentrations (nanodrop) were determined before a second 
amplification using primers provided in the kit.  PCR and analysis was performed as 
described above.   
ORF45/42 PCR products were used to direct cell-free protein synthesis using the 
EasyXpress Protein Synthesis kit (Qiagen).  To prepare the in vitro reactions, 8.75 µl of 
E. coli extract was added to 3.25 µl RNase-free water.  In a separate tube 1 µl of XE-
Solution was combined with 100 ng DNA from the two step PCR protocol.  The XE-
12 
 
DNA mix was then added directly to the tube containing the E. coli-water mix, and 10 µl 
of the EasyXpress Reaction Buffer was added.  The tube was incubated in a 37°C water 
bath for one hour and the proteins were analyzed by SDS-PAGE and Western blotting. 
Samples were prepared for SDS-PAGE in 1x laemmeli sample buffer and 10% 
beta-mercaptoethanol.  Samples were boiled for 10 min and loaded onto 10% Tris-
glycine gel and electrophoresed at 190 V until the pre-stained protein molecular weight 
marker had fully separated.  Proteins were transferred onto a nitrocellulose membrane 
using a semi-dry blotter (Pierce).  The membrane was blocked overnight at 40C in 5% 
milk dissolved in Tris-Buffered Saline containing 1% Tween-20 solution (TBST).  
Blocked membranes were washed three times for 10 min each with TBST.  Strep tagged 
proteins were detected with a polyclonal anti-Strep antibody (1:5000) and 6xHis tagged 
proteins were detected using a mouse anti-histidine monoclonal antibody (1:5000).  
Membranes were incubated with antibodies for one hour at room temperature followed 
by three, 10 minute washes with TBST.  An anti-rabbit HRP conjugated secondary 
antibody (1:40,000) for Strep tagged proteins, and an anti-mouse HRP conjugated 
secondary antibody (1:40,000) for 6xHis tagged proteins was applied for one hour at 
room temperature, followed by three, 10 minute washes with TBST.  Chemiluminescent 
detection was performed using equal parts of both reagents of the Super Signal West Pico 
Chemiluminscent Substrate System (Pierce) for five minutes, and the membranes were 
exposed to film and developed with Xomat developer.  However, this method did not 
express the quantity of protein necessary for interaction assays; therefore another method 
of protein expression was utilized. 
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Cloning into the pEZSeq Blue/White Cloning 
IPFW68 (Visalli, 2007, Fig. 3) was used for generation of ORF45 and ORF42 
with either N or C-terminal 6xHis tags or N or C-terminal Strep tags.  A two-step PCR 
(Qiagen EasyXpress) was performed using the appropriate oligonucleotide primers listed 
in Table 3 (IDT, Inc).  PCR and analysis was performed as described above.    
14 
 
Table 3.  Oligonucleotide primers developed for tagged ORF45 and ORF42 for two-step 
PCR. 
 
ORF 45 
N-terminal 
no tag 
 
5’-AGAAGGAGATAAACAATGTCATTGATAATGTT-3’ 
ORF 45 
C-terminal 
No Tag 
5’- ACCCAC 
GCGCATGTCGTAAAAAGCACCCAAATGTCATTGATAATGTT -3’ 
ORF45 
N-terminal 
6xHis 
 
5’- CTTGGTTAGTTAGTTATTAGTTTGTGTTGTGACTTGACG -3’ 
ORF45 
C-terminal 
6xHis 
 
5’-TGGTGATGGTGGTGACCCCAGTTTGTGTTGTGACTTGACG-3’ 
ORF45 
N-terminal 
Strep 
5’- AAAAGC 
GCTGAAAACCTGATCGAAGGCCGTATGTCATTGATAATGTT -3’ 
ORF45 
C-terminal 
Strep 
 
5’- GGATGAGACCAGGCAGAGTTTGTGTTGTGACTTGACG -3’ 
ORF 42 
N-terminal 
No Tag 
 
5’- AGAAGGAGATAAACAATGGGTATCCGAGGTCAAGAT -3’ 
ORF 42 
C-terminal 
No Tag 
 
5’- CTTGGTTAGTTAGTTATTATTTAATAGGCATAAACACGGAA -3’ 
ORF42 
N-terminal 
6xHis 
5’- ACCCAC 
GCACATGTCGTAAAAAGCACCCAAGGTATCCGAGGTCAAGAT -3’ 
ORF42 
C-terminal 
6xHis 
5’- TGGTGA 
TGGTGGTGACCCCATTTAATAGGCATAAACACGGAA -3’ 
ORF42 
N-terminal 
Strep 
5’- AAAAGC 
GCTGAAAACCTGATCGAAGGCCGTGGTATCCGAGGTCAAGAT -3’ 
ORF42 
C-terminal 
Strep 
 
5’- GGATGAGACCAGGCAGATTTAATAGGCATAAACACGGAA -3’ 
 
PCR products generated were cloned into the pEZSeq vector in Fig. 4 (Lucigen).  
Ligation reactions consisted of 5 ul of ~300 ng/µl insert DNA, 1.25 µl 4X pEZSeq Vector 
Premix (pEZSeq vector, ATP, and reaction buffer), 0.5 µl CloneSmart DNA Ligase, and 
water to 5 ul.  Ligation reactions were incubated at room temperature (~25°C) for 30 
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minutes followed by heat inactivation at 70°C for 15 minutes.  E. cloni 10G Chemically 
Competent Cells (Lucigen) were thawed on wet ice for the transformation reactions and 2 
µl of the ligation reaction was gently mixed with 20 ul cells.  Mixtures were incubated on 
ice for 30 minutes, subjected to heat shock in a 42°C water bath for 45 seconds and 
returned to ice for two minutes.  130 ul of room temperature Recovery Media was added 
and the transformation reaction was placed in a 37°C shaking incubator for one hour.  70 
µl of transformation mixture was plated in duplicate onto LB agar plates containing 30 
µg/ml kanamycin and 50 ug/ml x-gal and incubated overnight at 37°C.  One white colony 
was picked from each plate and grown in liquid LB media containing antibiotic overnight 
at 37°C.   Plasmid was extracted from the overnight culture using the PureYield plasmid 
miniprep kit (Promega). 
 
Fig. 4.  pEZSeq vector (Lucigen).  The vector contains a blunt cloning site that 
interrupts the lacZ coding sequence, resulting in white successful recombinant 
clones and blue non-recombinants.  The vector contained kanamycin resistance 
(http://www.frilabo.pt/Imgs/produtos/import/40526-1.Manual.pdf). 
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Plasmids were screened for insert DNA, via restriction digest with HindIII 
(Thermo Scientific).  Digest consisted of 5 µl of plasmid DNA, 2 µl of 10X restriction 
enzyme buffer, 1 µl of HindIII enzyme, and 12 µl of nuclease-free water.  After 
incubation for 5 minutes in a 37°C water bath, digest were analyzed on 0.8% agarose 
gels.  The restriction digests of the plasmid showed improper ligation of the amplified 
DNA in the vector, therefore a new method of cloning was performed. 
 
Protein Synthesis via the Expresso T7 Cloning and Expression System 
Primers (Table 4) were designed for amplification of full length ORF45/42, ORF45 (exon 
I), ORF42 (exon II), and four truncated forms of ORF42, all containing C-terminal 6xHis 
tags for the Expresso T7 system (Lucigen).  
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Table 4.  Oligonucelotide primers developed for tagged ORF42 and ORF42Δ constructs. 
 
 
 
ORF 
45/42 
Forward 5’- 
GAAGGAGATATACATATGTCATTGATAATGTTTGGTCG
T-3’ 
Reverse 5’- 
GTGATGGTGGTGATGATGTTTAATAGGCATAAACACG
GA-3’ 
 
ORF45 
Reverse 5’-
GTGATGGTGGTGATGATGGTTTGTGTTGTGACTTGACG
C-3’ 
 
ORF42 
Forward 5’- 
GAAGGAGATATACATATGGGTATCCGAGGTCAAGATT
TT-3’ 
ORF 42 
Δ 1 
Forward 5’- 
GAAGGAGATATACATATGAATTGTGCTATATTATCGTC
A-3’ 
ORF 42 
Δ 2 
Forward 5’- 
GAAGGAGATATACATATGTCGTCGGATCAGTTGTTAAA
CGTT-3’ 
ORF 42 
Δ 3 
Reverse 5’- 
GTGATGGTGGTGATGATGAACGTCTACGTTTGTAAATG
T-3’ 
ORF 42 
Δ 4 
Reverse 5’- 
GTGATGGTGGTGATGATGTTTACATAGATACTCCACGG
G-3’ 
 
 
 
PCR was performed using Phusion High-Fidelity DNA Polymerase (NEB, Inc) 
and IPFW68 as template.   
PCR: 
0.5 µl IPFW68    Initial denature: 98°C, 3 min 
1.25 µl forward primer   Denature: 98°C, 10s 
1.25 µl reverse primer    Anneal: 52°C, 30s 
5 µl HF Buffer    Extension: 72°C, 30s 
0.5 µl dNTP     Final Extension: 72°C, 5 min 
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0.25 µl Phusion polymerase   Total Cycles: 35 
15.5 µl water 
PCR products were cloned into pETite (Fig. 5) and transformed into HI-Control 
10G Chemically Competent kanamycin resistant cells (Lucigen).  2 µl (12.5 ng/ µl) of the 
pETite vector and 100 ng of PCR product were mixed with 20 ul of thawed HI-Control 
10G cells, incubated on ice for 30 minutes, heat shocked in a 42°C water bath for 45 
seconds and returned to ice for two minutes.  480 µl of room temperature recovery media 
was added to the transformation reaction and placed in a 37°C shaking incubator for 1 
hour.  100 µl of the transformation mixture was plated onto LB agar plates containing 30 
µg/ml kanamycin and incubated overnight at 37°C.  Two colonies from each plate were 
selected and grown in 2 ml of LB media containing antibiotic overnight at 37°C.  1 ml of 
overnight culture was centrifuged for plasmid extraction using the PureYield plasmid 
miniprep kit (Promega). 
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Fig. 5.  pETite expression vector (Lucigen).  The vector encodes a C-Terminal 
6xHis tag containing ORF42 and ORF42Δs.  ATG, translation start site; STOP, 
translation end site; and Kanamycin resistant (http://lucigen.com/docs/ 
manuals/MA101-Expresso-T7-Cloning-&-Expression-System.pdf). 
 
 
 
Plasmids were screened for insert DNA, via restriction digest with EcoRI for 
ORF45 and EcoRI and XbaI for ORF42 and ORF42Δs.  Digest consisted of 8 µl of 
plasmid DNA, 1 µl of 10X restriction enzyme buffer, and 1 µl of enzyme.  After 
incubation for 5 minutes in a 37°C water bath, digests were analyzed on 1.2% agarose 
gels.  The remaining LB cultures were centrifuged and stored in 100µl of freezing media 
(50% glycerol and 1x skim milk) and at -80°C.   
BL21(DE3) HI-Control cells, used for protein production, were transformed 
with1 ul of pETite vector clone.  Mixtures were incubated on ice for 30 minutes, 
subjected to heat shock in a 42°C water bath for 45 seconds, and returned to ice for two 
minutes.  480 µl of recovery media was added and the transformation reaction was placed 
in a 37°C shaking incubator for one hour.  100 µl of the transformation reaction was 
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plated in duplicate onto LB agar containing 30 µg/ml kanamycin and incubated overnight 
at 37°C.  Two colonies from each plate were picked transferred to LB media containing 
30 ug/ml kanamycin and grown overnight in a shaking incubator at 37°C.    
For protein production, 200 µl of overnight culture was transferred to 1 ml LB 
media containing antibiotic and placed in a 37°C shaking incubator for two hours to 
reach proper cell density (OD600: 0.5-1.0).  0.5 ml of culture was removed, centrifuged for 
one minute at 12,000 x g, and placed in 4°C.  The remaining culture was induced with 
1mM isopropyl-β-d-thiogalactopyranoside (IPTG) and returned to the shaking incubator 
for three hours, after which, the culture was centrifuged for one minute at 12,000 x g.  
Induced and non-induced pellets were analyzed via SDS-PAGE, Western blot and 
developed on via chemiluminscence as described above using mouse anti-histidine 
monoclonal antibody (1:4,000) and anti-mouse HRP conjugated secondary antibody 
(1:40,000).   
 
Partial Purification of ORF42 and ORF42Δs Proteins 
Induced and non-induced BL21(DE3) cells were harvested via 
microcentrifugation and resuspended in lysis buffer F containing 5 mg/ml lysozyme, 50 
mM Tris, 150 mM NaCl, 1% Triton X-100, 5 mM dithiothreitol (DDT), 3% sarkosyl, and 
protease inhibitor in phosphate buffered saline (PBS).  The suspension was sonicated on 
ice three times for 10 seconds, with one minute rests between sonications.  Cellular 
material and supernatants were collected, and analyzed via SDS-PAGE, Western blot via 
chemiluminescence as described above.  Proteins were distributed into small aliquots and 
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stored at -80°C for use in interaction studies.  (See appendix for additional methods of 
protein extraction).   
 
ORF42 and ORF42Δs Protein Purification 
ORF42 and ORF42Δs extracts were further purified with the HisPur Cobalt 
Purification Kit (Thermo Scientific).  Induced and un-induced cells were lysed as 
described above.  Supernatants were removed and mixed 1:1 with an Equilibration/Wash 
Buffer provided in the kit. This mixture was added to a HisPur Cobalt Column and mixed 
by end-over-end rocking for 30 minutes at 4°C.  The column was centrifuged for two 
minutes at 700 x g to remove the flow through and washed with 400 ul of wash buffer 
three times, discarding the flow through.  200 ul of Elution Buffer from the kit was added 
to the column and centrifuged for two minutes in a new collection tube.  The elution 
process was conducted three times; collecting each fraction in a new collection tube.  100 
ul of Elution Buffer was added to the column to extract 100 ul of elution/bead mixture to 
be analyzed.  The pellets, elution/bead mixtures, unpurified proteins, and the first elution 
were analyzed via SDS-PAGE and Western Blot as described above.   
 
Production of GST-Fusion Proteins 
GST fusion proteins were developed for use in interaction studies.  BL(DE3) cells 
were transformed with the pGEX-3X (GST) (Fig. 6), as well as pGEX-3X-C269 (GST-
ORF42-C269), encoding a GST fusion protein containing the C-terminal 269 amino acids 
of ORF45/42 (Visalli et al., 2007).  Cells containing either GST or GST-ORF42-C269 
plasmids were grown in 2X-YT media containing 0.1mg/ml ampicillin at 30°C at 225 
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rpm overnight.  A 1:1000 dilution of the overnight cultures to fresh media containing 
ampicillin was incubated for five hours at 30°C at 225 rpm to reach proper cell density 
(OD600: 0.5-1.0). Cultures were induced with 0.1mM IPTG for 16 hours at 30°C at 225 
rpm and were harvested via centrifugation at 7000 x g for 10 minutes, washed twice with 
PBS, and resuspended in a lysis buffer F and sonicated.  Supernatants and pellets were 
analyzed via SDS-PAGE and Western blot using mouse anti-GST monoclonal primary 
antibody (1:5000; Genescript) and anti-mouse HRP secondary antibody (1:20,000) as 
described above.   
 
 
Fig. 6.  pGEX-3X vector (GE healthcare).  The vector was used for GST and 
GST-ORF42-C269 clones (https://www.gelifesciences.com/gehcls_images/ 
GELS/Related%20Content/Files/1314787424814/litdoc28962284_201305241142
12.pdf). 
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GST Fusion Protein Incubation with Glutathione-Agarose Beads 
GST and GST-ORF42-C269 fusion proteins were adjusted to 1% sarkosyl, and 
100 ul bed volume of Glutathione-Agarose beads (Pierce) were washed twice with 
Equilibration/Wash buffer, containing 50 mM Tris, 150 mM NaCl in PBS pH 8.0.  1 ml 
of adjusted GST and GST-ORF42-C269 fusion protein was incubated on an end –over-
end rocker at room temperature overnight.  Beads were centrifuged for two min at 700 x 
g ,were washed five times for 10 minutes with cold PBS, and resuspended in Storage 
Buffer containing 50mM Hepes, pH 7.4, 150 mM NaCl, 5 mM DTT, 10% (v/v) glycerol, 
and a protease inhibitor cocktail (Visalli, 2007,2009).  The fusion proteins, supernatant 
after bead incubation, and bead immobilized protein were analyzed via SDS-PAGE, 
Western Blot as described above. 
Following HRP detection, the blot was analyzed with an alkaline phosphatase 
detection kit (Novagen).  After blocking for one hour using Protein-Free TBS Blocking 
Buffer (Pierce) at room temperature, the blot was stored overnight at 4°C.  The blot was 
washed in triplicate with TBST and treated with mouse anti-GST monoclonal antibody 
(1:5000; Genescript) for one hour at room temperature, followed by three washes with 
TBST.  An alkaline phosphatase-conjugated AffiniPure Goat Anti-Mouse secondary 
antibody (1:2,000; Protein Tech) was applied for one hour at room temperature followed 
by three additional TBST washes, and was then developed using equal parts of 3-bromo-
4-chloro-5-indolyl phosphate (BCIP) and nitro blue tetrazolium (NBT) to a solution of 
20x Buffer from the kit (Novagen) in TBST.  Once the blot was developed sufficiently, it 
was rinsed with water and dried overnight.  The glutathione-agarose beads were stored at 
4°C for pull-down experiments.   
24 
 
GST Pull-Down Assay 
25 ul bed volume of GST or GST-ORF42-C269 bead immobilized fusion protein 
were transferred to individual microcentrifuge tubes and washed twice with Binding 
Buffer containing 50 mM Hepes,150 NaCl, 5 mM DTT, 10% (v/v) Glycerol, 1% Triton-
X100, and Protease Inhibitor Cocktail in 1x PBS.  100 ul of 1% sarkosyl adjusted 
pORF42, pORF42Δ1, pORF42Δ2, pORF42Δ3, and pORF42Δ4 were added separately to 
both GST and GST-ORF42-C269 beads and incubated overnight on an end-over-end 
rocker at room temperature.  Samples were centrifuged gently and washed five times for 
10 minutes with binding buffer, removing the supernatant after each centrifugation.  The 
beads were analyzed by SDS-PAGE and Western Blot for GST and GST-ORF42-C269 
by HRP and developed via chemiluminscence as described above.  pORF42 and 
pORF42Δs were developed by alkaline phosphatase as described above. 
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RESULTS 
 
Amplification of ORF45/42 via the EasyXpress System 
The EasyXpress system was used to amplify ORF45/42 and generate a set of 
templates that could be translated into proteins with different combinations of affinity 
tags, 6xHis or Strep, on either terminus.  The 2-step PCR kit enabled DNA amplification 
directly from plasmid DNA or PCR product templates.  The first amplification adds 5’-
tails to the target gene using gene specific primers to act as a hybridization site for the 
second PCR.  The second amplification uses kit supplied primers, dependent upon the tag 
used, and codes for the regulatory elements for optimal expression in the linear protein 
expression kit. 
Linear templates of ORF45/42 with either a 6xHis C-terminal or Strep N-terminal 
tag were generated and analyzed on EtBr stained agarose gels (Fig. 7).  Amplicons were 
not successfully expressed from VZV genomic DNA (Ellen) (Fig. 7, lanes 1 and 3).  
Therefore IPFW68 plasmid containing the 2.3 kb ORF45/42 gene was used for the 
preparation of ORF45/42 N-terminal and C-terminal tags (Fig.7, lanes 2, 4, 5, and 6).
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Fig. 7.  PCR1 products of tagged ORF45/42.  (1) Ellen ORF45/42 C-terminal 6xHis, (2) 
IPFW68 ORF45/42 C-terminal 6xHis, (3)  Ellen ORF45/42 N-terminal Strep, (4) 
IPFW68 ORF45/42 N-terminal Strep, (5) IPFW68 ORF45/42 N-terminal 6xHis, (8) 
IPFW68 ORF45/42 C-terminal Strep. 
 
 
 
The amplicons from the first step PCR were used as templates in the second step 
PCR for the addition of specific sequences coding for regulatory elements used in the 
cell-free protein expression system.   The PCR products of ORF45/42 C-terminal 6xHis 
(Fig. 8 [1], lanes 1 and 2), ORF45/42 C-terminal Strep (Fig. 8 [1], lanes 3 and 4), and 
ORF45/42 N-terminal 6xHis (Fig. 8 [1], lanes 7 and 8) exhibited the expected DNA 
amplicons when analyzed on stained agarose gels.  DNA was quantitated via the 
NanoDrop spectrophotometer (0.7- 1.0 ug) prior to use in the cell-free protein synthesis 
system.  ORF45/42 N-terminal Strep was not successfully generated (Fig. 8 [1], lane 6), 
until adjustments in the protocol to lower the annealing temperature further (Fig. 8 [2], 
lanes 1 and 2).  The four PCR products that amplified correctly were used to synthesize 
protein. 
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Fig. 8.  [1] PCR1 and PCR2 products of tagged ORF45/42.  (1) PCR1 IPFW68 
ORF45/42 N-terminal 6xHis, (2) PCR2 IPFW68 ORF45/42 N-terminal 6xHis, (3) PCR1 
IPFW68 ORF45/42 C-terminal 6xHis, (4) PCR2 IPFW68 ORF45/42 C-terminal 6xHis, 
(5) PCR1 IPFW68 ORF45/42 N-terminal Strep, (6) PCR2 IPFW68 ORF45/42 N-terminal 
Strep, (7) PCR1 IPFW68 ORF45/42 C-terminal Strep, (8) PCR2 IPFW68 ORF45/42 C-
terminal Strep.  
[2] PCR1 and PCR2 products of N-terminal Strep tagged ORF45/42.  (1) PCR1 IPFW68 
ORF45/42 N-terminal Strep, (2) PCR2 IPFW68 ORF45/42 N-terminal Strep. 
 
 
 
Protein Synthesis of ORF45/42 via the EasyXpress System 
The EasyXpress Protein Synthesis Kit produces full-length recombinant proteins 
directly from plasmid or PCR product templates.  The kit consists of a cell-free system of 
E. coli cell lysates containing all necessary translational machinery and RNA 
polymerases.  Linear ORF45/42 DNAs containing the necessary regulatory elements 
were added to the kit components.  A western blot was performed with anti-strep 
antibody, and Proteins corresponding to tagged version of pORF45/42 were observed 
(Fig. 9).   
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Fig. 9.  Protein expression of tagged ORF45/42 constructs. (1) PageRuler Plus Protein 
ladder, (2) Positive control, (3): pORF45/42 N-terminal Strep, (4): pORF45/42 C-
terminal Strep.   
 
 
 
Several strategies were attempted to increase pORF45/42 protein expression.  
Modifications included the addition of RNAse inhibitor and incubation at both 37°C and 
30°C,and addition of RNAse inhibitor and 1% Glycerol at 37°C.  Unfortunately, 
expression of the full-length pORF45/42 strep tagged proteins was never adequate 
enough for used in protein-protein interaction experiments.   
 
Amplification of Separate ORF45 and ORF42 Exons via the EasyXpress System 
The EasyXpress system was used to amplify the two ORF45/42 exons separately 
for two reasons: (1) due to difficulty in expressing full length protein and (2) to determine 
which exon is responsible for self-interaction.   
Primers were designed for ORF45 and ORF42 containing 6xHis tags or Strep tags 
on either terminus.  All four tagged versions of the ORF42 sequence and the N-terminal 
6xHis and Strep tagged versions of the ORF45 sequence were successfully amplified in 
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PCR step 1.  The second amplification of these sequences resulted in four amplicons 
suitable for protein cloning and expression via the pEZSeq Blue/White Cloning Kit:  
ORF45 N-terminal 6xHis (Fig. 10, Lanes 2 and 3) tagged sequence, both ORF42 N (Fig. 
10, Lanes 4 and 5) and C-terminal 6xHis (Fig. 10, Lanes 6 and 7) tagged sequences, and 
ORF42 N-terminal Strep (Fig. 10, Lanes 8 and 9) tagged sequences seen in Fig. 10.   
 
 
Fig. 10.  PCR1 and PCR2 of tagged ORF45 and ORF42 constructs.  (1) 1Kb DNA ladder 
(NEB), (2) PCR1 ORF45 N-terminal 6xHis, (3) PCR2 ORF45 N-terminal 6xHis, (4) 
PCR1 ORF42 N-terminal 6xHis, (5) PCR2 ORF42 N-terminal 6xHis, (6) PCR1 ORF42 
C-terminal 6xHis, (7) PCR2 ORF42 C-terminal 6xHis, (8) PCR1 ORF42 N-terminal 
Strep, (9) PCR2 ORF42 N-terminal Strep. 
 
 
 
ORF45 and ORF42 pEZSeq Blunt Cloning and Blue/White Screen 
The pEZSeq Blunt Cloning Kit utilizes a blue/white screen to detect recombinant 
clone interruption of the coding sequence for the lacZα peptide by target DNA.  When 
the vector is transformed into E. cloni and plated on XGAL/IPTG indicator plates, the 
recombinants are white colonies, whereas those lacking the insert DNA appear as blue 
colonies.  Cloning of PCR products into the pEZSeq vector and transformation into E. 
cloni cells did not yield any ligation products when analyzed on an agarose gels after 
restriction digestion.  The cloned products may have been unstable in this system and 
hence another method was used for cloning and expression.  
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Expresso T7 Cloning of ORF45, ORF42, and ORF42Δs 
The Expresso T7 cloning system was used for its simplicity and rapid enzyme-
free directional cloning by combining the PCR product with the pETite vector.  This 
system was employed since there was no need for purification of the PCR product for 
proper ligation.  PCR products can be transformed directly into the HI-Control 10G 
Competent Cells for recombination into the pETite vector, allowing recovery of the 
desired plasmid DNA.  These cells had been optimized for high efficiency transformation 
and limited protein expression (cells lack the T7 RNA polymerase and expresses the lac 
repressor in excess).  
New PCR products were generated for proper ligation into the pETite vector.  
Primers were designed for ORF45/42 full length, as well as ORF45 and ORF42 
separately.  In addition, four truncated ORF42 constructs were created based on the 
proposed self-interaction site mapped in the HCMV homolog UL89, by Nadal et al.  Fig. 
11.1 shows the amplification of ORF45 (Lane 3), ORF42 (Lane 4), and ORF42Δ1 (Lane 
5).  Amplification of ORF42Δ2, ORF42Δ3, and ORF42Δ4 were more complex. 
Modification to annealing temperature and extension time, and buffer substitutions 
including the addition of 3% DMSO were required for successful amplification.  For 
example, GC buffer, which is recommended for amplification of sequences rich in GC 
residues, was used to amplify the templates.  Fig. 11.2 shows three PCR modifications for 
amplification of ORF42Δ2 (Lanes 2, 3, and 4), ORF42Δ3 (Lanes 5, 6, and 7), and 
ORF42Δ4 (Lanes 8, 9, and 10).  The 10x HF buffer and addition of 3% DMSO amplified 
the target gene for all three ORF42Δ constructs.  
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Fig. 11.  [1] PCR of tagged ORF45/42, ORF45, and ORF42 constructs from plasmid 
DNA. (1) 1kb DNA ladder, (2) ORF45/42, (3) ORF45, (4) ORF42, (5) ORF42Δ1. 
[2] PCR of tagged ORF42 constructs from plasmid DNA with a selection of buffers.  
Plasmid was amplified with 10xHF buffer in lanes (2),(5), & (8), 10xHF buffer and 3% 
DMSO in lanes (3),(6), & (9), and 1xGC buffer in lanes (4),(7), & (10).  (1) 1 kb DNA 
ladder, (2),(3), & (4) ORF42Δ2, (5),(6), & (7) ORF42Δ3, (8),(9), & (10) ORF42Δ4.  
 
 
 
PCR products were transformed into HI-Control 10G Competent Cells and 
individual colonies isolated for analysis.  The predicted restriction digests with either 
EcoR1 or XbaI are listed in Table 5.  The sites were determined by using PlasMapper 
(Dong et al., 2004) to identify unique restriction sites within the vector and insert DNA, 
seen in appendix 1.  Two colonies of ORF45 were digested with EcoRI which resulted in 
the expected size fragments of 1335 bp and 1956 bp on a stained agarose gel (Fig. 12.1).  
ORF45 colony two resulted in clearer fragments than colony one, and was used for 
further transformation in BL21(DE3) cells.  ORF42 and ORF42Δ1 were digested with 
both XbaI and EcoRI to ensure proper ligation.  ORF42-XbaI (Lane 1) was expected to 
digest into two sized fragments of 1215 bp and 2208 bp on a stained agarose gel, which 
are shown in Fig. 12.2.  Furthermore, two ORF42Δ1 colonies were digested with EcoRI 
into two fragments of sizes seen in Fig. 12.2, and both colonies display correct ligation, 
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however colony two was chosen for further use.  Two colonies of each remaining 
ORF42Δ construct were digested using EcoRI.  These samples were expected to digest 
into three sized fragments, all of which contain a 1962 bp fragment.   Both colonies for 
ORF42Δ2 showed correct fragmentation seen in Fig. 12.3, however only one colony for 
both ORF42Δ3 (Lane 4) and ORF42Δ4 (Lane 5) had fragments of correct size on the 
stained agarose gel.  Plasmids confirmed by restriction digest were used to transform into 
the BL21(DE3) cells for protein expression. 
 
Table 5.  DNA fragment size after restriction digest. 
ORF Amplicon size with EcoRI 
digest (bp) 
Amplicon size with XbaI 
digest 
(bp 
ORF45 1335 1956  
ORF42 531 929 1963 1215 2208 
ORF42Δ1 1051 1956 799 2208 
ORF42Δ2 356 930 1962  
ORF42Δ3 530 456 1962  
ORF42Δ4 530 753 1962  
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Fig. 12.  [1] Restriction digest of positive control and ORF45 with EcoRI and XbaI.  (1) 
1kb DNA ladder, (2) Positive control + EcoRI, (3) Positive control + XbaI, (4) ORF45 
colony 1 + EcoRI, (5) ORF45 colony 2 + EcoRI. 
[2] Restriction digest of tagged ORF42 constructs with XbaI and EcoRI.  (1) ORF42 
colony 1 + XbaI, (2),(5) ORF42Δ1 colony 1 + XbaI, (3),(6) ORF42Δ1 colony 2 + XbaI, 
(4) ORF42 colony 1 + EcoRI, (5) ORF42Δ1 colony 1 + EcoRI, (6) ORF42Δ1 colony 2 + 
EcoRI.   
[3] Restriction digest of tagged ORF42 constructs with EcoRI.  (1) ORF42Δ2 colony 1, 
(2) ORF42Δ2 colony 2, (3) ORF42Δ3 colony 1, (4) ORF42Δ3 colony 2, (5) ORF42Δ4 
colony 1, (6) ORF42Δ4 colony 2. 
*Lane 4 and 5 expressed correct fragments for ORF42Δ3 and ORF42Δ4, respectively. 
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Protein Expression of ORF45, ORF42, and ORF42Δs via the Expresso T7 System 
Protein expression is facilitated through transformation of the vector into the 
BL21(DE3) cells.  These cells contain the T7 RNA polymerase gene, used to initiate 
protein production when the T7 promoter is induced with 1 mM IPTG.  This promoter 
controls the expression of the T7 RNA polymerase, which in turn controls the expression 
of the target gene insert. 
BL21(DE3) cells transformed with pETite clones of ORF45, ORF42, and 
ORF42Δ1 and grown overnight on LB agar.  Individual colonies were transferred to 
liquid LB and screened for protein expression by inducing a portion of culture with 1mM 
IPTG.  Protein expression was analyzed via SDS-PAGE and Western blotting.  Un-
induced cells exhibited basal expression of the T7 promoter leading to leaky expression 
of target protein.  Fig. 13 shows the induced and un-induced protein expression (in boxes) 
of ORF45 (Lanes 1-4), ORF42 (Lanes 5-8), and ORF42Δ1 (Lanes 9-12).  Protein 
expression in the induced samples for ORF42 (Lanes 6 and 8) and ORF42Δ1(Lanes 10 
and 12) were in higher quantity than those seen in the un-induced samples and were at the 
expected size of 43.9 kDa and 26.7 kDa, respectively. The approximate sizes of the 
ORF42 and ORF42Δ proteins can be seen in Table 6 and a diagram depicting the relative 
sizes to one another can be seen in Fig. 14. 
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Fig. 13.  Induced and un-induced cultures of tagged ORF45 and ORF42 constructs 
analyzed via western blot for protein expression.  (1),(3) un-induced ORF45, (2),(4) 
induced ORF45, (5),(7) un-induced ORF42, (6),(8)induced ORF42, (9),(11) un-induced 
ORF42Δ. 
 
 
Table 6.  Approximate size of pORF42 and pORF42Δ constructs.  
 
ORF ORF42 ORF42Δ1 ORF42Δ2 ORF42Δ3 ORF42Δ4 
Protein Size 
(kDa) 
43.9 26.7 37.5 26.4 37.4 
 
 
 
 
Fig. 14.  Diagram of pORF42 and pORF42Δ constructs.  
 
 
 
ORF42 and ORF42Δ1 vector clones were transformed into fresh BL21(DE3) cells 
to decrease the level of leaky expression of target protein.  Induced and un-induced 
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cultures were analyzed via SDS-PAGE and Western blotting in Fig. 15.  The un-induced 
cultures of ORF42 (Lanes 2 and 4) and ORF42Δ1 (Lanes 6 and 8) displayed decreased 
levels of protein compared to the induced cultures. 
 
 
Fig. 15.  Protein expression in induced and un-induced ORF42 and ORF42Δ1 cultures.  
(1) & (3) un-induced pORF42 (2) & (4) induced pORF42, (5) & (7) un-induced 
pORF42Δ1, (6) & (8) induced pORF42Δ1. 
 
 
 
Expression of the target protein had been accomplished; however it was necessary 
to extract soluble protein from the cells to be used for interaction assays.  While several 
methods of extraction were tested, Fig. 16.1 displays the use of binding buffer with 1% 
Triton X-100 as a solution used with sonication of the culture.  The binding buffer was 
not as effective as lysis buffer G in tandem with sonication, as seen in Fig. 16.2.  While 
all the pellets contained target protein, cultures sonicated with lysis buffer G contained 
more soluble protein in the supernatant, for example: Fig. 16.1, Lanes 1 and 2, compared 
to Fig 16.2, Lanes 1 and 2.  Although these results were encouraging, it was decided to 
purify pORF42 and pORF42Δ1 using column chromatography to enhance protein 
quality. 
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Fig. 16.  [1] Induced cultures of ORF42 constructs treated and sonicated in binding buffer 
and 1% Triton X-100. (1) ORF42 supernatant, (2) ORF42Δ1 supernatant, (3) & (5) 
ORF42Δ2 post-lysis pellet, (4) & (6) ORF42Δ2 supernatant, (7) & (9) ORF42Δ3 post-
lysis pellet, (8) & (10) ORF42Δ3 supernatant, (11) & (13) ORF42Δ4 post-lysis pellet, 
(12) & (14) ORF42Δ4 supernatant.   
[2] Induced ORF42 and ORF42Δ cultures sonicated in lysis buffer G containing 3% 
sarkosyl. (1) ORF42 supernatant, (2) ORF42Δ1 supernatant, (3) & (5) ORF42Δ2 post-
lysis pellet, (4) & (6) ORF42Δ2 supernatant, (7) & (9) ORF42Δ3 post-lysis pellet, (8) & 
(10) ORF42Δ3 supernatant, (11) & (13) ORF42Δ4 post-lysis pellet, (12) & (14) 
ORF42Δ4 supernatant. 
 
 
 
ORF42 and ORF42Δs Protein Purification via HisPur Colbalt Purification Kit 
The HisPur Cobalt Purification Kit is designed for efficient purification of 
recombinant His-tagged proteins from soluble protein extract using immobilized metal 
affinity chromatography.  Often this technique is performed using nickel for the 
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purification of His-tagged proteins; however the Cobalt kit had been optimized not only 
for high yield, but also purity. 
Induced cultures of ORF42 and ORF42Δ1were sonicated in lysis buffer A and the 
supernatants were applied to the purification columns.  Samples of the post-lysis pellet, 
supernatant, and three column elutions were analyzed via SDS-PAGE and Western blot 
(Fig. 17).  There was no evidence of protein in the supernatants (Lanes 1 and 6) or the 
elutions (Lanes 3-5 and 8-10), even after a one hour exposure to film; the only proteins 
present were in the post-lysis pellet sample (Lanes 2 and 7).  Hence, the proteins were 
insoluble and required detergents for release from inclusion bodies. 
 
 
Fig. 17.  HisPur Cobalt purification of pORF42 and pORF42Δ1 pellets and elutions after 
sonication in lysis buffer A.  (1) pORF42 induced supernatant, (2) pORF42post-lysis 
pellet, (3) pORF42 elution 1, (4) pORF42 elution 2, (5) pORF42 elution 3, (6) 
pORF42Δ1 induced supernatant, (7) pORF42Δ1 post-lysis pellet, (8) pORF42Δ1 elution 
1, (9) pORF42Δ1 elution 2, (10) pORF42Δ1 elution 3. 
 
 
 
The purification process was repeated with sonication of ORF42 and ORF42Δ1 in 
lysis buffer A and lysis buffer B, which contained 8 M urea. 8 M urea is commonly used 
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to solubilize proteins contained in inclusion bodies.  The treated supernatants were 
applied to the cobalt columns and incubated.  Samples of the post-lysis pellet, 
supernatant, first column elution, and column beads after the elutions were analyzed via 
SDS-PAGE and Western blot (Fig. 18 [1], 18 [2]).  After sonication in lysis buffer A, a 
large amount of protein still remained bound in the pellet. Some pORF42Δ1 (Fig 18 [2], 
Lane 4) was present in the elution sample from lysis buffer A.  The ORF42 culture 
sonicated in lysis buffer B had increased amounts of protein in the supernatant for (Fig 18 
[1], Lane 7) as well as protein bound to the beads after elution (Fig. 18 [1], Lane 6).  The 
ORF42Δ1 culture sonicated in lysis buffer B had increased amount of protein present in 
the elution (Fig. 18 [2], Lane 8), but protein was also present on the beads after elution 
(Fig. 18 [2], Lane 6), unlike the samples treated in lysis buffer A.  pORF42 and 
pORF42Δ1 were both detected in the eluted sample when treated with lysis buffer A (Fig 
18 [1], Lane 4, Fig. 18 [2], Lane 4), however only pORF42Δ1 was present in the elution 
after sonicated with lysis buffer B (Fig. 18 [1], Lane 8, Fig. 18 [2], Lane 8).   
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Fig. 18.  [1] Protein extraction and purification of pORF42 extracted with lysis buffer A 
(1-4) and lysis buffer B (5-8) after HisPur Cobalt purification.  (1) post-lysis pellet, (2) 
beads, (3) supernatant, (4) column elution, (5) post-lysis pellet, (6) beads, (7) supernatant, 
(8) column elution.   
[2] Protein extraction and purification of pORF42Δ1 extracted with lysis buffer A (1-4) 
and lysis buffer B (5-8) after HisPur Cobalt purification.  (1) post-lysis pellet, (2) beads, 
(3) supernatant, (4) column elution, (5) post-lysis pellet, (6) beads, (7) supernatant, (8) 
column elution. 
 
 
 
Glutathione S-Transferase-Fusion Protein Expression 
pGEX-3X vector (GST) and pGEX-3X-C269 (GST-ORF42-C269) were 
transformed into BL21(DE3) cells and used for production of GST-fusion proteins via 
induction with 1 mM IPTG .  The cultures were resuspended in lysis buffer D and 
sonicated.  Supernatants were incubated with anti-glutathione s-transferase agarose beads 
overnight and the post-lysis pellet and beads were analyzed via SDS-PAGE and Western 
blot using anti-GST primary antibody (1:5000; Genescript) and anti-mouse HRP 
secondary antibody (1:20,000) seen in Fig. 19.1.  GST and GST-ORF42-C269 were 
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present in the pellet with little to no purification on the beads.  Therefore the cultures 
were treated with lysis buffer E and sonicated more vigorously.  The effect of sonication 
on solubility can be seen in Fig. 19.2, where lysis buffer E and sonications were able to 
extract protein (Lanes 2-4) efficiently from the post-lysis pellet, however the post-lysis 
pellet (Fig. 19.2,Lane 1) still contained insoluble fusion protein.  The changes in lysis 
buffer and sonication had dissimilar effects upon GST-ORF42-C269, where fusion 
protein was only present in the post-lysis pellet (Fig 19.2, Lane 5).  GST was released 
from the pellet to a greater extent than GST-ORF42-C269; therefore a modified lysis 
buffer and sonication method was employed. 
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Fig. 19.  [1] GST and GST-ORF42-C269 extraction and bead attachment after treated 
with lysis buffer D.  (1): GST pellet, (2) GST beads, (3) GST-ORF42-C269 pellet, (4) 
GST-ORF42-C269 beads.   
[2] GST and GST-ORF42-C269 extraction in lysis buffer E after each sonication.  (1) 
GST pellet, (2) GST sample 1, (3) GST sample 2, (4) GST sample 3, (5) GST-ORF42-
C269 pellet, (6) GST-ORF42-C269 sample 1, (7) GST-ORF42-C269 sample 2, (8) GST-
ORF42-C269 sample 3. 
*Overflow of sample in Lane 5 accounts for the protein seen partially in lane 6. 
 
 
 
Lysis buffer E was shown to be inefficient in solubilizing GST-ORF42-C269 and 
could not be detected in any of the supernatant samples.  Therefore another detergent 
(sarkosyl) and extended incubation times were used with sonication to release the fusion 
proteins. GST (Fig. 20.2) and GST-ORF42-C269 (Fig. 20.1) cultures were resuspended 
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in lysis buffer E (Fig. 20.1, Lanes 1-4 and Fig. 15.2, Lanes 3-6) and lysis buffer F, 
containing 10% sarkosyl (Fig. 20.1, Lanes 5-8 and Fig. 15.2, Lanes 7-10), but with 
incubation on ice for one hour prior to sonication.  Lysis buffer F released GST-ORF42-
C269 from the pellet and was clearly detected in each of the supernatant samples; GST 
was also released effectively in lysis buffer F.  Lysis buffer E was able to extract GST 
(Fig. 20.2, Lanes 4-6), similar to the previous trial, however less protein was present in 
the post-lysis pellet, due to the extended incubation time.  The effect of lysis buffer E on 
GST-ORF42-C269, was also similar to the previous trial.  There was no presence of 
protein apparent in any of the supernatants until the last sonication (Fig. 20.1, Lane 4).  
Lysis buffer F was more efficient in solubilizing the protein in GST and GST-ORF42-
C269.  The pellets retained little protein (Fig. 20.1, Lane 5, Fig. 20.2, Lane 7) when 
compared to the amount present in the supernatant samples (Fig. 20.1, Lanes 6-8, Fig. 
20.2, Lanes 8-10). 
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Fig. 20.  [1] Concentration of protein extraction of GST-ORF42-C269 with lysis buffer E 
(1-4) and lysis buffer F (5-8).  (1) pellet, (2)  sample 1, (3) sample 2, (4) sample 3, (5) 
pellet, (6) sample 1, (7) sample 2, (8) sample 3. 
[2] Concentration of protein extraction of GST with lysis buffer E (3-6) and lysis buffer F 
(7-10).  (1) supernatant 3 from 9-1-2011, (2) 9-11-2011 supernatant on beads, (3) pellet, 
(4): sample 1, (5): sample 2, (6) sample 3, (7) pellet, (8) sample 1, (9) sample 2, (10) 
sample. 
 
 
 
GST and GST-ORF42-C269 cultures were lysed using differing concentrations of 
sarkosyl to determine the minimum amount needed to release protein into the 
supernatant, since high concentrations of detergent could have negative effects on 
downstream interaction experiments.  Fig. 21.1 and Fig. 21.2 show the results of lysis 
buffer E, originally made with 10% sarkosyl, was made with 3% (Lanes 1 and 2), 5% 
(Lanes 3 and 4), 8% (Lanes 5 and 6), and 10% (Lanes 7 and 8) sarkosyl and sonicated.  
Post-lysis pellets and supernatants were analyzed via SDS-PAGE and Western blot using 
anti-GST primary antibody (1:5000) and anti-mouse AP secondary antibody (1:2,000) 
seen in Fig. 21.1 (GST) and Fig. 21.2 (GST-ORF42-C269).   
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Both fusion protein samples reacted to the increasing sarkosyl concentration 
similarly, as the concentration of sarkosyl increased, protein solubility improved, 
however the lower the concentration of sarkosyl the lower the risk of excessive 
denaturation of the protein.  This was important since the proper structure and folding of 
the protein is necessary to evaluate protein-protein interactions. There did not appear to 
be a significant difference in the solubility of GST as the sarkosyl concentration was 
increased, as seen in Fig. 21.1, excluding the 10% sarkosyl treatment (Lanes 7 and 8).  
Fig. 21.2 showed the solubility differences of each treatment on GST-ORF42-C269, 
however the 3% treatment (Lanes 1 and 2) and 5% treatment (Lanes 3 and 4) displayed 
the most similar amount of soluble protein, but differed from the high concentrations of 
sarkosyl (Lanes 5-8).  It was determined that the lysis buffer containing the 3% sarkosyl 
(lysis buffer G) was the best solution to solubilize the protein with the minimal amount of 
detergent needed.  However, if the protein solubilized with lysis buffer F, which released 
more protein into the supernatant, was still able to be purified on beads, it might prove to 
be a better treatment due to increased concentration of protein available for bead 
attachment. 
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Fig. 21.  [1] Effect of protein extraction of GST when lysed with 3%, 5%, 8%, and 10% 
sarkosyl concentrations in lysis buffer F.  (1) 3% sarkosyl post-lysis pellet, (2) 3% 
sarkosyl supernatant, (3) 5% sarkosyl post-lysis pellet, (4) 5% sarkosyl supernatant, (5) 
8% sarkosyl post-lysis pellet, (6) 8% sarkosyl supernatant, (7) 10% sarkosyl post-lysis 
pellet, (8) 10% sarkosyl supernatant.   
[2] Effect of protein extraction of GST-ORF42-C269 when lysed with 3%, 5%, 8%, and 
10% sarkosyl concentrations in lysis buffer F.  (1) 3% sarkosyl post-lysis pellet, (2) 3% 
sarkosyl supernatant, (3) 5% sarkosyl post-lysis pellet, (4) 5% sarkosyl supernatant, (5) 
8% sarkosyl post-lysis pellet, (6) 8% sarkosyl supernatant, (7) 10% sarkosyl post-lysis 
pellet, (8) 10% sarkosyl supernatant.  
 
 
 
GST and GST-ORF42-C269 Incubations with Glutathione-Agarose Beads 
Glutathione agarose beads are designed for purification of GST-fusion proteins 
from cell lysates.  However, the extraction treatment of GST and GST-ORF42-C269 
involved the addition of sarkosyl, which could inhibit the attachment of the fusion protein 
onto the bead.  Therefore, it was necessary to adjust the sarkosyl concentration of the 
supernatants containing the fusion proteins.  It was determined to test the proteins 
extracted from both the 3% sarkosyl (lysis buffer G) and the 10% sarkosyl (lysis buffer 
F).  The soluble GST-ORF42-C269 proteins from lysis buffer F and G were adjusted to 
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decrease the sarkosyl concentration to 1% and incubated with the beads.  Protein from 
supernatants and beads were analyzed via SDS-PAGE and Western blot with anti-GST 
primary antibody (1:5000) and anti-mouse AP secondary antibody (1:2,000) (Fig. 22).  
There was not an apparent difference in the concentrations from the use of lysis buffer F 
(Fig. 22, Lane 1 and 2) or (7) (Fig. 22, Lane 3 and 4), nor the affinity to the beads.  
Therefore, lysis buffer G was used to extract protein, due to the decreased concentration 
of detergent present.  
 
 
 
Fig. 22.  The effect of bead attachment to GST-ORF42-C269 at 3% and 10% sarkosyl 
concentration.  (1) 3% sarkosyl GST-ORF42-C269 supernatant, (2) 3% sarkosyl GST-
ORF42-C269 + beads, (3) 10% sarkosyl GST-ORF42-C269 supernatant, (4) 10% 
sarkosyl GST-ORF42-C269 + beads. 
 
 
 
As seen in Fig. 22 (Lanes 1 and 3), there was some protein left in the supernatant 
after incubation on the beads. To optimize protein attachment, incubation was conducted 
at 4°C (Fig. 23, Lane 1), 25°C (Fig. 23, Lane 2), and 37°C (Fig. 23, Lane 3) to determine 
if the temperature affected bead attachment. GST-ORF42-C269 was incubated with 100 
ul of beads at different temperatures overnight; however temperature did not dramatically 
affect the bead attachment except for incubation at 37°C, which generated unusable beads 
by dissolving them into a sludge-like consistency.   
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Fig. 23.  Incubation of Glutathione agarose beads with pGST-ORF42-C269 at 4°C (1), 
25°C (2), and 37°C (3).  There was no apparent difference in quality of bead attachment 
at 4°C and 25°C.   
 
 
 
Examining Protein-Protein Interactions for ORF42 Exon II:  The GST Pull-Down Assay 
The GST pull down assay was designed to determine any interaction between 
pORF42 and the pORF42Δs with bead immobilized GST-ORF42-C269, in order to 
establish possible sites of exon II that have the ability to interact with itself.  GST was 
designed to ascertain a negative control for interaction with pORF42 and pORF42Δs.  A 
diagram of GST and GST-ORF42-C269 in Fig. 24, illustrates how the bead and fusion 
protein attach to allow interaction between the fusion protein and the pORF42 constructs.  
Immobilized GST and GST-ORF42-C269 were incubated with each of the five pORF42 
variants.  If there is any presence of interaction, the target pORF42 constructs will be 
weighed down by the agarose bead, therefore when the beads are washed and removed 
for analysis, both the GST fusion protein and the target protein will be present.  The 
detection of GST (Fig. 25, lanes 1-6) and GST-ORF42-C269 (Fig. 25, lanes 7-12) were 
analyzed via HRP with anti-GST primary antibody (1:5000) and anti-mouse HRP 
secondary antibody (1:20,000).  
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Fig. 24.  Diagram of immobilized GST and GST-ORF42-C269. 
 
 
 
 
Fig. 25. GST pull-down and presence of GST (1-6) and GST-ORF42-C269 (7-12) 
detected through HRP. 
 
 
 
After the detection of GST and GST-ORF42-C269, the blot was washed and 
readied for further protein detection.  pORF42 (Fig. 26, Lanes 2 and 8), pORF42Δ1 (Fig. 
26, Lanes 3 and 9), pORF42Δ2 (Fig. 26, Lanes 4 and 10), pORF42Δ3 (Fig. 26, Lanes 5 
and11), and pORF42Δ4 (Fig. 26, Lanes 6 and 12) products were detected using mouse 
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anti-histidine monoclonal antibody (1:4,000) and anti-mouse AP conjugated secondary 
antibody (1:2,000).    
 
 
Fig. 26.  GST pull-down of pORF42 and pORF42Δs detected through AP.  (1) GST, (2) 
GST + pORF42, (3) GST + pORF42Δ1, (4) GST + pORF42Δ2, (5) GST + pORF42Δ3, 
(6) GST + pORF42Δ4, ( ): GST-ORF42-C269, (8) GST-ORF42-C269 + pORF42, (9) 
GST-ORF42-C269 + pORF42Δ1, (10): GST-ORF42-C269 + pORF42Δ2, (11) GST-
ORF42-C269 + pORF42Δ3, (12) GST-ORF42-C269 + pORF42Δ4.  pORF42, 
pORF42Δ1, and pORF42Δ2 all appeared to interact with GST-ORF42-C269, however 
pORF42Δ3 and pORF42Δ4 were not present on the blot, indicating that they were not 
able to interact with GST-ORF42-C269.  
 
 
 
Comparison of the two blots from Fig. 25 and Fig. 26 suggests that there is a 
region in pORF42 important in self-interaction.   There did not appear to by any active 
interaction among the negative control, GST, and any of the pORF42 constructs.  
However, pORF42 (Fig. 26, Lane 8), and the N-terminal deletions pORF42Δ1 (Fig. 26, 
Lane 9) and pORF42Δ2 (Fig. 26, Lane 10) interacted with the ORF42 fusion protein, 
GST-ORF42-C269 (Fig. 25, Lanes 7-12), indicating that the binding site was still present 
in those constructs. The truncated proteins produced from the C-terminal deletions, 
pORF42Δ3 (Fig. 26, Lane 11) and pORF42Δ4 (Fig. 26, Lane 12), did not interact with 
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immobilized GST-ORF42-C269, suggesting that they no longer contained the self-
interaction binding site.   Therefore, this assay determined that the pORF42 Exon II self-
interaction binding site is located near the C-terminus between Glutamine-689 and the C-
terminus of pORF42, and not in the predicted area at residues 492-507 on the full length 
pORF45/42. The predicted interaction site was approximately 200 residues away from 
the site that exhibited interaction in the GST pull-down assay. 
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DISCUSSION 
 
The identification of essential viral protein-protein interactions provides novel 
and specific targets for antiviral chemotherapy. Herpesviridae encode a collection of 
proteins that function to cleave and package viral DNA into preformed capsids.  
Encapsidation protein functions and interactions have been extensively studied in HSV, 
and more modestly investigated for HCMV and VZV.  Protein-protein interactions within 
the HSV-1 terminase subunits have been previously observed (Abbotts et al., 2000; 
Koslowski et al., 1999; Sheaffer et al., 2001; Yang and Baines, 2006).  Similar 
interactions have been observed for HCMV and VZV.  For example, the VZV terminase 
subunits pORF25 and pORF45/42 are capable of displaying self-interaction (Hwang and 
Bogner, 2002; Thoma et al., 2006; Visalli, 2007; 2009).  Determining specific interaction 
sites within one or more subunits offers the possibility of antiviral therapies that can 
target these interactions, prevent viral DNA packaging, and inhibit viral replication 
(Bogner, 2002). 
To determine a potential intramolecular interaction site for the VZV terminase 
subunit, pORF45/42, truncated versions of the protein were expressed and prepared for 
use in GST pull-down assays.  GST-pORF42-C269 fusion protein or GST alone were 
combined with the 6xHis tagged pORF42 and pORF42Δs, to identify the region of 
pORF42 responsible for self-interaction.  
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Western blots of pull-down assays showed the interaction of GST-pORF42-C269 
with pORF42, pORF42Δ1, and pORF42Δ2 but not with pORF42∆3 or ∆4.  This result 
suggested that the self-interaction site within pORF42 was located within the C-terminal 
region of the protein.   Previous studies by Nadal et al. suggested that the interaction site 
was located in the N-terminal region of exon-II of the HCMV terminase homolog and 
therefore should not have been retained in pORF42Δ1 and pORF42Δ2.  Since 
pORF42Δ1 and pORF42Δ2 were present in the pull-down assay with GST-pORF42, a 
novel or additional terminase interaction site for VZV pORF45/42 must be located in a 
different region than HCMV.  Importantly, the truncated proteins that did not interact, 
pORF42Δ3 and pORF42Δ4, contained a C-terminal deletion further indicating that the 
interaction site is on the C-terminal portion of the pORF42.   
There are several important questions to be answered with additional research.  
Which exon-II residues are important in the self-interaction? Is the interaction site critical 
for complete terminase activity?  Does this interaction site influence interactions with 
other terminase subunits, i.e. pORF30 and pORF25.  Co-immunoprecipitation 
experiments using in vitro synthesized tagged versions of the other terminase subunits 
could be used to determine interactions.   Lysates of cells transfected with tagged 
subunits and/or co-precipitation of the authentic subunits from VZV infected cells will be 
necessary to confirm their importance during viral replication. 
While many proteins and their respective interactions are conserved throughout 
the Herpesviridae, individual interactions may differ between the alpha, beta, and gamma 
subfamilies.  For example, the proposed exon-II interaction site in HCMV, a member of 
the gamma subfamily, was not present in VZV, an alphaherpesvirus.  I would 
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hypothesize that this interaction would be conserved within the gamma subfamily due to 
the overlap in structure and function.  Similarly, interactions observed for VZV might be 
expected to be conserved of HSV 1 and 2, other alpha subfamily members.   
Small molecule compounds or peptides that inhibit intramolecular or 
intermolecular interactions within the terminase complex could yield novel strategies to 
treat one or more of the human herpesviruses.  Current therapies are primarily DNA 
polymerase inhibitors (i.e acyclovir and ganciclovir), which target viral DNA replication.  
Generally, these drugs are either not readily bioavailable or resistance can develop 
(Visalli, 2003).  A new drug, letermovir, under stage II clinical trials for HCMV infection 
in transplant patients, targets the terminase subunit pUL89 and prevents cleavage of  
newly synthesized DNA.   This innovative treatment differs from current therapies by 
targeting the late replication cycle, ability to be given prophylactically, and used in 
tandem with the current drug therapies.  The novel approach of targeting unique aspects 
of the viral replication cycle is necessary due to resistance to current therapies and in 
treating and preventing herpesviral infections (Chemaly, et al., 2014; Griffiths and 
Emery, 2014).   
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Appendix A: Lysis Buffers 
 
Lysis Buffer A 
1% Triton X-100    Sonication 
Phosphate Buffered Saline  3x- 10s 
Protease Inhibitor cocktail  Setting #2 
 
Lysis Buffer B 
1% Triton X-100   Sonication 
8 M Urea    3x- 10s 
Phosphate Buffered Saline  Setting #2 
Protease Inhibitor cocktail   
 
Lysis Buffer C 
1.5% Sarkosyl    Sonication 
25 mg/ml lysozyme   3x- 10s 
Phosphate Buffered Saline  Setting #2 
Protease Inhibitor Cocktail 
 
Lysis Buffer D 
5 mg/ml lysozyme   Sonication 
1.5% sarkosyl    3x- 10s 
0.1% Triton X-100   Setting #2 
Protease Inhibitor Cocktail 
Phosphate Buffered Saline 
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Lysis Buffer E    
5 mg/ml lysozyme   Sonication 
50 mM Tris    1x- 10s, centrifuge 1 min to collect sample 
150 mM NaCl    1x-1 min, centrifuge 1 min to collect sample 
1% Triton X-100   1x-1 min, centrifuge 1 min to collect sample 
Protease Inhibitor Cocktail  Setting #2 
Phosphate Buffered Saline  
 
Lysis Buffer F  
5 mg/ml lysozyme   Sonication 
50 mM Tris    1x- 10s, centrifuge 1 min to collect sample 
150 mM NaCl    1x-1 min, centrifuge 1 min to collect sample 
1% Triton X-100   1x-1 min, centrifuge 1 min to collect sample 
10% Sarkosyl    Setting #2 
5 mM DTT 
Protease Inhibitor Cocktail 
Phosphate Buffered Saline 
 
Lysis Buffer G 
5 mg/ml lysozyme   Sonication 
50 mM Tris    3x- 10s 
150 mM NaCl    Setting #2 
1% Triton X-100 
3% Sarkosyl 
5 mM DTT 
Protease Inhibitor Cocktail 
Phosphate Buffered Saline 
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 Storage Buffer 
50 mM Hepes     
150 NaCl     
5 mM DTT 
10% (v/v) Glycerol 
Protease Inhibitor Cocktail 
Phosphate Buffered Saline 
 
Binding Buffer 
50 mM Hepes     
150 NaCl     
5 mM DTT 
10% (v/v) Glycerol 
1% Triton-X100 
Protease Inhibitor Cocktail 
Phosphate Buffered Saline 
 
Equilibration/Wash Buffer 
50 mM Tris 
150 mM NaCl 
Phosphate Buffered Saline 
pH 8.0 
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Appendix B: Restriction Sites in pETite Vector Recombinant Clones 
 
 
Fig. B1.  ORF45 and ORF42 recombinant clone depicting restriction sites. 
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Fig. B2. ORF42Δ1 and ORF42Δ2 recombinant clone depicting restriction sites. 
 
 
 
 
Fig. B3.  ORF42Δ3 and ORF42Δ4 recombinant clone depicting restriction sites. 
